Friday, October 2, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 27, 2025

XRP’s Historic December 2017 Surge Revisited—Could 2025 Set Up a Similar Move?

View original at finance.yahoo.com
XRP’s Historic December 2017 Surge Revisited—Could 2025 Set Up a Similar Move? Tsikhanovich Alena / Shutterstock.com Quick Read XRP rallied 1,200% in 6 weeks (December 2017): $0.25 to $3.30 driven by retail FOMO, exchange listings, Bitcoin hitting $20K…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 2025 replaces retail mania with institutional firepower: $1.1B ETF inflows in 4 weeks, SEC settlement August 2025, RLUSD at $1B market cap

    80% confidence

  • A repeat of the 1,200% rally is possible in December 2025 if catalysts, sentiment, adoption, and structure align

    80% confidence

  • Steady 50-100% gains could push XRP to $3-4 by mid-2026, or price could remain range-bound between $1.80-$2.50 as institutions accumulate slowly

    80% confidence

  • Over 1.35 billion XRP tokens have been removed from circulation into long-term custody, representing 45% less supply available for sale

    80% confidence

  • Social media was flooded with 'XRP to $10' predictions during the 2017 rally

    80% confidence

  • XRP rallied 1,200% in 6 weeks from December 2017, driven by retail FOMO, exchange listings, and Bitcoin hitting $20K

    80% confidence

  • 2017 had zero institutional participation vs measured allocations in 2025; no regulatory clarity vs SEC settlement; pure speculation vs banks using ODL ($1.3B quarterly)

    80% confidence

Data points we hold from this source

XRP · circulating supply reduction1.35 billion_tokens
XRP · stock price range1.80-2.20 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com
XRP’s Historic December 2017 Surge Revisited—Could 2025 Set Up a Similar Move? — Source | Via News | Finance Via News